711 related articles for article (PubMed ID: 27149571)
1. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
[TBL] [Abstract][Full Text] [Related]
2. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Amdur RJ; Tepper J; Qaqish B; Green R; Aumer SL; Hayes N; Weiss J; Grilley-Olson J; Zanation A; Hackman T; Funkhouser W; Sheets N; Weissler M; Mendenhall W
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):976-85. PubMed ID: 26581135
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
[TBL] [Abstract][Full Text] [Related]
6. Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design.
Ward MC; Ross RB; Koyfman SA; Lorenz R; Lamarre ED; Scharpf J; Burkey BB; Joshi NP; Woody NM; Prendes B; Houston N; Reddy CA; Greskovich JF; Adelstein DJ
JAMA Otolaryngol Head Neck Surg; 2016 Dec; 142(12):1164-1170. PubMed ID: 27438230
[TBL] [Abstract][Full Text] [Related]
7. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
8. Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires.
Holländer-Mieritz C; Johansen J; Johansen C; Vogelius IR; Kristensen CA; Pappot H
Acta Oncol; 2019 May; 58(5):603-609. PubMed ID: 30698098
[No Abstract] [Full Text] [Related]
9. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
[TBL] [Abstract][Full Text] [Related]
12. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6).
Ringash J; Waldron JN; Siu LL; Martino R; Winquist E; Wright JR; Nabid A; Hay JH; Hammond A; Sultanem K; Hotte S; Leong C; El-Gayed AA; Naz F; Ramchandar K; Owen TE; Montenegro A; O'Sullivan B; Chen BE; Parulekar WR
Eur J Cancer; 2017 Feb; 72():192-199. PubMed ID: 28040660
[TBL] [Abstract][Full Text] [Related]
13. Long term patient reported swallowing function following chemoradiotherapy for oropharyngeal carcinoma.
Dixon L; Ramasamy S; Cardale K; Dyker K; Garcez K; Lee LW; McPartlin A; Murray P; Sen M; Slevin N; Sykes A; Prestwich R; Thomson D
Radiother Oncol; 2018 Sep; 128(3):452-458. PubMed ID: 29937211
[TBL] [Abstract][Full Text] [Related]
14. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.
Anderson CM; Lee CM; Saunders DP; Curtis A; Dunlap N; Nangia C; Lee AS; Gordon SM; Kovoor P; Arevalo-Araujo R; Bar-Ad V; Peddada A; Colvett K; Miller D; Jain AK; Wheeler J; Blakaj D; Bonomi M; Agarwala SS; Garg M; Worden F; Holmlund J; Brill JM; Downs M; Sonis ST; Katz S; Buatti JM
J Clin Oncol; 2019 Dec; 37(34):3256-3265. PubMed ID: 31618127
[TBL] [Abstract][Full Text] [Related]
15. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
Mavroidis P; Price A; Fried D; Kostich M; Amdur R; Mendenhall W; Liu C; Das S; Marks LB; Chera B
Radiother Oncol; 2017 Aug; 124(2):240-247. PubMed ID: 28712533
[TBL] [Abstract][Full Text] [Related]
16. Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: A prospective investigation of acute swallowing and toxicity patterns.
Moroney LB; Helios J; Ward EC; Crombie J; Pelecanos A; Burns CL; Spurgin AL; Blake C; Kenny L; Chua B; Hughes BGM
Head Neck; 2018 Sep; 40(9):1955-1966. PubMed ID: 29756244
[TBL] [Abstract][Full Text] [Related]
17. Gastrostomy tube placement in patients with oropharyngeal carcinoma treated with radiotherapy or chemoradiotherapy: factors affecting placement and dependence.
Bhayani MK; Hutcheson KA; Barringer DA; Lisec A; Alvarez CP; Roberts DB; Lai SY; Lewin JS
Head Neck; 2013 Nov; 35(11):1634-40. PubMed ID: 23322563
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
Theunissen EA; Zuur CL; Józwiak K; Lopez-Yurda M; Hauptmann M; Rasch CR; van der Baan S; de Boer JP; Dreschler WA; Balm AJ
JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma.
Hosni A; Dixon PR; Rishi A; Au M; Xu W; Song Y; Chepeha DB; Goldstein DP; Huang SH; Kim J; O'Sullivan B; Waldron J; Bratman SV; de Almeida JR
JAMA Otolaryngol Head Neck Surg; 2016 Dec; 142(12):1208-1215. PubMed ID: 27812692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
